Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Suciu · SciRah

Researcher profile · Semantic Scholar

S. Suciu

Share profile

S. Suciu — researcher profile on SciRah

h-index: 76
Works: 341
Citations: 21K

Most-cited papers

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
A. Eggermont, C. Blank, M. Mandalà, G. Long +25 more
2018New England Journal of Medicine1,601 citations Open access
Semantic Scholar
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
A. Eggermont, V. Chiarion-Sileni, J. Grob, R. Dummer +23 more
2016New England Journal of Medicine1,227 citations Open access
Semantic Scholar
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
A. Eggermont, V. Chiarion-Sileni, J. Grob, R. Dummer +18 more
2015The Lancet Oncology1,141 citations
Semantic Scholar
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo
A. Eggermont, M. Kicinski, C. Blank, M. Mandalà +26 more
2020JAMA Oncology376 citations Open access
Semantic Scholar
Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial.
S. Amadori, S. Suciu, D. Selleslag, F. Aversa +20 more
2016Journal of Clinical Oncology328 citations Open access
Semantic Scholar
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
A. Eggermont, C. Blank, M. Mandalà, G. Long +27 more
2021The Lancet Oncology327 citations Open access
Semantic Scholar
Meta-Analysis in Metastatic Uveal Melanoma to Determine Progression-Free and Overall Survival Benchmarks: an International Rare Cancers Initiative (IRCI) Ocular Melanoma study.
L. Khoja, E. Atenafu, S. Suciu, S. Leyvraz +22 more
2019Annals of Oncology259 citations Open access
Semantic Scholar
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
A. Eggermont, C. Blank, M. Mandalà, G. Long +27 more
2020Journal of Clinical Oncology234 citations Open access
Semantic Scholar
Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation
M. Mohty, K. Hübel, N. Kroger, M. Aljurf +24 more
2014Bone Marrow Transplantation194 citations Open access
Semantic Scholar
High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
R. Willemze, S. Suciu, G. Meloni, B. Labar +37 more
2014Journal of Clinical Oncology176 citations Open access
Semantic Scholar
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial.
A. Eggermont, V. Chiarion-Sileni, J. Grob, R. Dummer +16 more
2019European Journal of Cancer163 citations Open access
Semantic Scholar
An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions
E. Clappier, M. Auclerc, J. Rapion, M. Bakkus +21 more
2014Leukemia159 citations
Semantic Scholar
Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.
S. Leyvraz, S. Piperno-Neumann, S. Suciu, J. Baurain +12 more
2014Annals of Oncology135 citations Open access
Semantic Scholar
Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma.
A. Eggermont, M. Kicinski, C. Blank, M. Mandalà +26 more
2022NEJM Evidence134 citations
Semantic Scholar
IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951
E. Clappier, N. Grardel, M. Bakkus, J. Rapion +22 more
2015Leukemia107 citations
Semantic Scholar
Phase III trial (EORTC 18071 / CA184-029) of post-operative adjuvant ipilimumab compared to placebo in patients with resected stage III cutaneous melanoma: Health Related Quality of Life (HRQoL) results
C. Coens, S. Suciu, V. Chiarion-Sileni, J. Grob +17 more
2017The Lancet Oncology95 citations Open access
Semantic Scholar
Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant Therapy
S. Suciu, A. Eggermont, P. Lorigan, J. Kirkwood +10 more
2018Journal of the National Cancer Institute91 citations Open access
Semantic Scholar
Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
A. Eggermont, S. Suciu, P. Rutkowski, W. Kruit +6 more
2016European Journal of Cancer86 citations
Semantic Scholar
Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.
A. Eggermont, V. Chiarion-Sileni, J. Grob, R. Dummer +16 more
2014Journal of Clinical Oncology82 citations
Semantic Scholar
Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group
M. Lübbert, S. Suciu, A. Hagemeijer, B. Rüter +20 more
2015Annals of Hematology80 citations Open access
Semantic Scholar
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.
A. Eggermont, C. Blank, M. Mandalà, G. Long +28 more
2019European Journal of Cancer75 citations
Semantic Scholar
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
A. Bottomley, C. Coens, J. Mierzynska, C. Blank +30 more
2021The Lancet Oncology58 citations Open access
Semantic Scholar
Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts
C. Garbe, U. Keim, S. Suciu, T. Amaral +17 more
2020Journal of Clinical Oncology55 citations Open access
Semantic Scholar
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
O. Kennedy, M. Kicinski, S. Valpione, S. Gandini +27 more
2022European Journal of Cancer50 citations Open access
Semantic Scholar
Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial
Mariam G. Aslanyan, L. Kroeze, S. Langemeijer, Theresia N. Koorenhof-Scheele +20 more
2014Annals of Hematology30 citations
Semantic Scholar
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.
A. Eggermont, A. Meshcheryakov, V. Atkinson, C. Blank +30 more
2021European Journal of Cancer27 citations Open access
Semantic Scholar
Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5‐aza‐2′‐deoxycytidine (Decitabine)
M. Lübbert, G. Ihorst, Philipp N. Sander, L. Bogatyreva +5 more
2017British Journal of Haematology27 citations
Semantic Scholar
Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up.
A. Eggermont, C. Blank, M. Mandalà, G. Long +16 more
202026 citations
Semantic Scholar
Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951
V. Mondelaers, S. Suciu, B. De Moerloose, A. Ferster +19 more
2017Haematologica26 citations Open access
Semantic Scholar
Melanoma burden by melanoma stage: Assessment through a disease transition model.
I. Tromme, C. Legrand, B. Devleesschauwer, Ulrike Leiter +9 more
2016European Journal of Cancer25 citations Open access
Semantic Scholar
Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial.
A. Eggermont, V. Chiarion-Sileni, J. Grob, R. Dummer +16 more
2019Journal of Clinical Oncology23 citations
Semantic Scholar
Multiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients of the EORTC18961 trial
J. Michels, N. Becker, S. Suciu, I. Kaiser +10 more
2018Oncoimmunology22 citations Open access
Semantic Scholar
Prognostic and predictive value of YKL-40 in stage IIB-III melanoma
M. Krogh, I. Christensen, M. Bouwhuis, J. Johansen +6 more
2016Melanoma research22 citations
Semantic Scholar
Results of successive EORTC‐CLG 58 881 and 58 951 trials in paediatric T‐cell acute lymphoblastic leukaemia (ALL)
M. Hofmans, S. Suciu, A. Ferster, P. Van Vlierberghe +19 more
2019British Journal of Haematology21 citations Open access
Semantic Scholar
Fetal hemoglobin induction during decitabine treatment of elderly patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: a potential dynamic biomarker of outcome
Julia Stomper, G. Ihorst, S. Suciu, Philipp N. Sander +7 more
2018Haematologica21 citations Open access
Semantic Scholar
Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
O. Kennedy, M. Kicinski, S. Valpione, S. Gandini +26 more
2023European Journal of Cancer20 citations Open access
Semantic Scholar
Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors.
E. Coart, S. Suciu, P. Squifflet, E. Saad +6 more
2020European Journal of Cancer19 citations
Semantic Scholar
QbD APPROACH IN THE DEVELOPMENT OF ORAL LYOPHILISATES WITH IBUPROFEN FOR PAEDIATRIC USE
S. Suciu
2018Farmacia18 citations Open access
Semantic Scholar
The prognostic value of IKZF1plus in B‐cell progenitor acute lymphoblastic leukemia: Results from the EORTC 58951 trial
M. Kicinski, C. Arfeuille, N. Grardel, M. Bakkus +9 more
2023Pediatric Blood & Cancer16 citations Open access
Semantic Scholar
Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia
S. Galimberti, M. Devidas, A. Lucenti, G. Cazzaniga +15 more
2018JNCI Cancer Spectrum15 citations Open access
Semantic Scholar
Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients
F. Baron, F. Efficace, L. Cannella, R. Willemze +20 more
2020Haematologica14 citations Open access
Semantic Scholar
Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long‐term follow up of a phase III study
F. Baron, F. Efficace, L. Cannella, P. Muus +24 more
2020American journal of hematology/oncology14 citations Open access
Semantic Scholar
Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial: An international randomized double-blind phase III trial.
C. Coens, A. Bottomley, C. Blank, M. Mandalà +16 more
2018Annals of Oncology14 citations Open access
Semantic Scholar
Long‐term outcome evaluation of medium/high risk acute lymphoblastic leukaemia children treated with or without cranial radiotherapy in the EORTC 58832 randomized study
C. Piette, S. Suciu, Y. Bertrand, A. Uyttebroeck +19 more
2019British Journal of Haematology13 citations Open access
Semantic Scholar
Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy.
I. Tromme, C. Legrand, B. Devleesschauwer, Ulrike Leiter +7 more
2016European Journal of Cancer13 citations Open access
Semantic Scholar
CD200/BTLA deletions in pediatric precursor B-cell acute lymphoblastic leukemia treated according to the EORTC-CLG 58951 protocol
Farzaneh Ghazavi, E. Clappier, T. Lammens, S. Suciu +24 more
2015Haematologica13 citations Open access
Semantic Scholar
Quality of life of long‐term childhood acute lymphoblastic leukemia survivors: Comparison with healthy controls
Sofia Chantziara, J. Musoro, A. Rowsell, C. Sleurs +16 more
2022Psycho-Oncology12 citations Open access
Semantic Scholar
Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype
F. Baron, M. Stevens-Kroef, M. Kicinski, G. Meloni +16 more
2018Haematologica12 citations Open access
Semantic Scholar
Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013)
T. de Witte, S. Suciu, L. Meert, C. Halkes +6 more
2015Annals of Hematology12 citations Open access
Semantic Scholar
Milk Oral Lyophilizates with Loratadine: Screening for New Excipients for Pediatric Use
Sonia Iurian, Cătălina Bogdan, S. Suciu, D. Muntean +5 more
2022Pharmaceutics11 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Eggermont×17
Invite
A. Eggermont — researcher profile on SciRah
P. Ascierto×16
Invite
P. Ascierto — researcher profile on SciRah
C. Robert×16
Invite
C. Robert — researcher profile on SciRah
J. Grob×15
Invite
J. Grob — researcher profile on SciRah

×15

Invite

M. Kicinski — researcher profile on SciRah

Invite

C. Blank — researcher profile on SciRah

M. Mandalà×12

Invite

M. Mandalà — researcher profile on SciRah

V. Atkinson×12

Invite

V. Atkinson — researcher profile on SciRah

D. Schadendorf×12

Invite

D. Schadendorf — researcher profile on SciRah

Invite

G. Long — researcher profile on SciRah

Invite

A. Haydon — researcher profile on SciRah

Invite

M. Carlino — researcher profile on SciRah